Report cover image

Choroidal Neovascularization Market Report by Product Type (Intravenous, Intravitreal), Diagnosis (Fluorescein Angiography (FA), Indocyanine Green (ICG) Angiography, Spectral Domain Optical Coherence Tomography (OCT), and Others), Treatment Type (Angiogen

Publisher IMARC Services Pvt. Ltd.
Published Aug 10, 2024
Length 149 Pages
SKU # IMRC19102881

Description

Choroidal Neovascularization Market Report by Product Type (Intravenous, Intravitreal), Diagnosis (Fluorescein Angiography (FA), Indocyanine Green (ICG) Angiography, Spectral Domain Optical Coherence Tomography (OCT), and Others), Treatment Type (Angiogenesis Inhibitors Injection, Photodynamic Therapy, Laser photocoagulation, Low-dose Radiation Therapy, Surgery), Application (Extreme Myopia, Malignant Myopic Degeneration, Age-Related Developments), and Region 2024-2032


The global choroidal neovascularization market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.

Choroidal neovascularization (CNV) refers to the creation of new blood vessels in the choroid layer of the eyes affecting the Bruch's membrane and retinal pigment epithelium (RPE). Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision. At present, a combination of procedures, such as fluorescein angiography (FA), indocyanine green (ICG) angiography and optical coherence tomography (OCT) scanning, are utilized for diagnosing CNV. As per the results, doctors then prescribe anti-vascular endothelial growth factor (VEGF) drugs, thermal laser treatment and photodynamic therapy (PDT), to prevent the growth of the blood vessels.

The market is experiencing growth on account of the rising prevalence of age-related macular degeneration (ARMD), ocular histoplasmosis, pathologic myopia, angioid streaks, choroidal tears and inflammatory diseases of the choroid and retina. Moreover, the increasing geriatric population, which is more vulnerable to serious health conditions, is acting as another key factor bolstering the market growth. Furthermore, the growing adoption of combination drugs, along with the introduction of long-lasting anti-VEGF drugs, is propelling the demand for CNV treatments worldwide. Other factors, such as improving healthcare infrastructure and the increasing investments in research and development (R&D) activities, are also contributing to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global choroidal neovascularization market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, type of diagnosis, treatment type and application.

Breakup by Product Type:
  • ntravenous
  • ntravitreal
Breakup by Type of Diagnosis:
  • Fluorescein Angiography (FA)
  • ndocyanine Green (ICG) Angiography
  • Spectral Domain Optical Coherence Tomography (OCT)
  • Others
Breakup by Treatment Type:
  • Angiogenesis Inhibitors Injection
  • Photodynamic Therapy
  • Laser photocoagulation
  • Low-dose Radiation Therapy
  • Surgery
Breakup by Application:
  • Extreme Myopia
  • Malignant Myopic Degeneration
  • Age-Related Developments
Breakup by Region:
  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Bausch Health Companies Inc., Bayer AG, Gilead Sciences, Inc., F. Hoffmann-La Roche AG, MaaT Pharma, Novartis AG, Pfizer Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Regeneron Pharmaceuticals Inc. and Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).

Key Questions Answered in This Report:
  • How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global choroidal neovascularization market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the type of diagnosis?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global choroidal neovascularization market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

149 Pages
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Choroidal Neovascularization Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Intravenous
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Intravitreal
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Type of Diagnosis
7.1 Fluorescein Angiography (FA)
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Indocyanine Green (ICG) Angiography
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Spectral Domain Optical Coherence Tomography (OCT)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Treatment Type
8.1 Angiogenesis Inhibitors Injection
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Photodynamic Therapy
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Laser Photocoagulation
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Low-dose Radiation Therapy
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Surgery
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Application
9.1 Extreme Myopia
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Malignant Myopic Degeneration
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Age-Related Developments
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Bausch Health Companies Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bayer AG
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Gilead Sciences, Inc.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 F. Hoffmann-La Roche AG
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.5 MaaT Pharma
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Novartis AG
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Pfizer Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Quark Pharmaceuticals Inc. (SBI ALApharma Co., Limited)
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.9 Regeneron Pharmaceuticals Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Sanwa Kagaku Kenkyusho Co. Ltd. (SUZUKEN CO., LTD.)
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us